RecruitingPhase 2NCT04056962
Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma
Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma：a Randomized Controlled Study
Sponsor
West China Hospital
Enrollment
50 participants
Start Date
Sep 1, 2019
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of this study was to evaluate the efficacy and safety of topical application of tacrolimus at different concentrations for superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
Eligibility
Min Age: 0 YearsMax Age: 18 Years
Inclusion Criteria1
- Children with superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA)
Exclusion Criteria1
- Hypersensitivity to Tacrolimus Mucosal Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA)
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTacrolimus ointment
topical application of tacrolimus at different concentrations for treatment of superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04056962